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Background: Possible interactions between nervous and immune systems in neuro-psychiatric disorders remain
elusive. Levels of brain dopamine transporter (DAT) have been implicated in several impulse-control disorders, like
attention deficit / hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). Here, we assessed the
interplay between DAT auto-immunity and behavioural / neurochemical phenotype.
Methods: Male CD-1 mice were immunized with DAT peptide fragments (DAT-i), or vehicle alone (VEH), to
generate elevated circulating levels of DAT auto-antibodies (aAbs). Using an operant delay-of-reward task (20 min
daily sessions; timeout 25 sec), mice had a choice between either an immediate small amount of food (SS), or a
larger amount of food after a delay (LL), which increased progressively across sessions (from 0 to 150 sec).
Results: DAT-i mice exhibited spontaneous hyperactivity (2 h-longer wake-up peak; a wake-up attempt during rest).
Two sub-populations differing in behavioural flexibility were identified in the VEH control group: they showed
either a clear-cut decision to select LL or clear-cut shifting towards SS, as expected. Compared to VEH controls,
choice-behaviour profile of DAT-i mice was markedly disturbed, together with long-lasting alterations of the striatal
monoamines. Enhanced levels of DA metabolite HVA in DAT-i mice came along with slower acquisition of basal
preferences and with impaired shifting; elevation also in DOPAC levels was associated with incapacity to change a
rigid selection strategy. This scarce flexibility of performance is indicative of a poor adaptation to task contingencies.
Conclusions: Hyperactivity and reduced cognitive flexibility are patterns of behaviour consistent with enduring
functional impairment of striatal regions. It is yet unclear how anti-DAT antibodies could enter or otherwise affect
these brain areas, and which alterations in DAT activity exactly occurred after immunization. Present
neuro-behavioural alterations, coming along with an experimentally-induced rise of circulating DAT-directed aAbs,
open the issue of a potential role for auto-immunity in vulnerability to impulse-control disorders.
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Besides the core symptoms of hyperactivity, impulsivity
and impaired sustained attention, which are also found
in other syndromes, children with attention-deficit
hyperactivity disorder (ADHD) often display accompany-
ing socio-behavioural difficulties, including defiant-
opponent symptoms and disinhibited conduct [1].
According to the dominant model, ADHD is viewed as* Correspondence: Walter.Adriani@iss.it
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reproduction in any medium, provided the oran executive dysfunction [2,3], but alternative accounts
present ADHD as a motivational dysfunction [4], arising
from altered processes within fronto-striatal circuits
[5,6]. Frequently comorbid with ADHD, obsessive-
compulsive disorder (OCD) is a chronic, progressive dis-
order with a prevalence of 1-4%. OCD is essentially an
impulse-control disorder, commonly comorbid to symp-
toms like compulsive shopping and/or sex, pathological
gambling, Tourette's syndrome [7,8], and may also be
conceptualized as part of the addictive disorder
spectrum [9]. In fact, more than half of ADHD patientsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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personality, as well as substance abuse / dependence
problems [10,11].
In both ADHD and OCD, a lack of self-control capaci-
ties may provide the ground for involvement in extreme
and risky activities, such as those typical of the
sensation-seeking supertrait [12]. There is substantial
genetic influence in impulse-control disorders: for in-
stance, the dopamine D4 receptor (DRD4) is the proto-
typic polymorphic gene, subserving a background for
novelty- and risk- seeking [13,14], addiction [15] as well
as both ADHD and OCD [16-18]. Among studies de-
scribing alteration of dopamine systems in ADHD and/
or OCD, it has been proposed that specific symptoms
may arise from a modification in dopamine transporter
(DAT) expression and function [19-22]. In this line, a
rising interest exists for auto-immune processes and
psycho-immunological interactions (see e.g. [23-25])
which - among other non-genetic factors that obviously
play a considerable role - may account for such possible
DAT alterations.
Although the blood–brain barrier (BBB) forms a tight
seal that might impede circulating molecules entering
into the CNS [26,27], the immune system appears to
have no mechanism to prevent the production of anti-
bodies against brain antigens, making it likely that there
could be an antibody-centred immune response in the
context of a BBB breakdown [28,29]. A breach in BBB
integrity can be caused under conditions of stress [30],
or owing to a traumatic injury to the brain (TBI) like e.g.
as complication of a difficult delivery [31]. Once admit-
ted the possibility of a BBB failure, implications include
drainage of CNS antigens to peripheral lymphoid organs,
with subsequent auto-immune response towards the
CNS: these potentially self-directed antibodies (i.e. auto-
antibodies, aAbs) may recognize a wide range of CNS
proteins, including AMPA and NMDA glutamate recep-
tors [32]. Conversely, whenever the integrity of BBB is
compromised, different molecules including aAbs can
freely reach the CNS.
Besides Systemic Lupus Erythematosus (SLE), a proto-
typical disease caused by anti-nuclear antibodies [33],
neuron-binding aAbs have been detected in sera from
several patients: aAbs to glutamate receptors have been
evidenced in intractable seizures [34,35] or brain ische-
mic stroke [36]. In the context of neuro-psychiatry,
autoimmune responses are common in Hashimoto’s en-
cephalopathy, Sydenham’s chorea, chronic opiate addic-
tions [37], as well as OCD and schizophrenia [25].
Interestingly, similarly to other pediatric autoimmune
neuropsychiatric disorders associated with streptococcal
infection (PANDAS), the development of Tourette’s
syndrome in children and in adolescents [38,39] has
also been ascribed to anti-neuronal antibodies. Thus,symptoms of ADHD may partially share some pathogen-
esis’ steps, if not etiology, with Tourette’s and/or OCD:
in that some symptoms may be proposed as a neuro-
psychiatric sequel of a streptococcal infection [23,24,40].
Circulating aAbs to several CNS antigens can be
detected in experimental animal models [41-46], as well
as in opiate-treated mice [47]. Presently, we have
hypothesized that anti-DAT aAbs could cross the BBB,
reach DAT proteins on neuronal synapses, and hence
produce reactions culminating in a long-term functional
interference over these neurons. Although presently un-
able to cover all steps of such hypothesis, as a prelimin-
ary study we generated an auto-immune response
possibly interfering with DAT function, and then tested
in-vivo the long-term consequences. In particular, mice
were immunized with two synthetic fragments, whose
design was based on DAT protein sequence, to generate
a rise in DAT-targeting aAbs. Such auto-immune chal-
lenge could in turn lead to an enduring and possibly
detectable interference with the dopamine (DA) neuro-
transmission as well as to DA-related behavioural
changes. Aim of and rationale for this investigation was
to test whether some ADHD and/or OCD behavioural
symptoms, like impulsive and/or compulsive behaviour,
may be generated in-vivo via an auto-immune challenge.
Methods
All procedures were approved by the local Animal Sur-
vey Committee, on behalf of Italian Ministry of Health,
and were carried out in accordance with the European
Community Council directive (86/609/EEC) and Italian
Law. All efforts were made to minimize animal suffering,
to reduce the number of animals used, and to use alter-
natives to in-vivo testing.
Animals and immunization
Male CD-1 mice (Charles River, Calco, Italy), at weaning
age (21 days old, PND 21) upon arrival, were housed in
pairs within Plexiglas cages (33 × 13 × 14 cm) and kept
at constant temperature (22 ± 1°C), upon a reversed
light/dark cycle (lights on from 20.00 to 08.00). Food
(Altromin-R, A. Rieper S.p.A., Vandoies, Italy) and water
were available ad libitum.
The experiment was run in two batches of mice (see
Experimental Scheme 1): mice of batch I (N = 24) were
sacrificed on PND 49, after immunization and boost, to
verify the generation of circulating DAT aAbs; mice of
batch II (N = 24) underwent a test battery, to evaluate
long-term changes in behaviour after immunization and
boost. Following arrival of each batch, after seven days
of acclimation, mice were randomly assigned to two
groups, i.e. DAT-immunized (DAT-i) or vehicle controls
(VEH, n = 10–14 per group). DAT-i mice were injected
intraperitoneally (i.p.) with Freund’s Adjuvant vehicle,
Scheme 1 Experimental design, showing mice in batch I
(N = 24) and batch II (N = 24).
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then the Incomplete (IFA, boost at PND 46). Plasma
levels of DAT aAbs were monitored in mice of both
batches, to prove effective immunization. Body-weight
of mice was monitored in batch II, on PND 32, 68, 76
and daily during the delay-of-reward task (PND 83–99),
to detect any possible effect on bodyweight gain, due to
or following immunization.
The immunogen was formed by peptide fragments,
designed by one of us (O.G.) by selecting a 19-
aminoacid portion of the DAT sequence based on the
most immuno-reactive portion (U.S. Patent and Trade-
mark Office: EFS ID 13464574; Application Number:
61681638; Granstrem et al. 10-AUG-2012 provisional
patent), and custom synthesized (DiaPharm Ltd. Russia).Such immunogen was used within CFA or IFA emulsion
for immunization and boost. For each animal, the
immunogen (60 μg) was dissolved in 0.125 ml sterile sa-
line and prepared by adding 0.125 ml CFA or IFA, to
form a stable emulsion [48]. Control mice received a
VEH treatment without any immunogen, i.e. an emul-
sion of sterile saline plus either CFA (at PND 34) or IFA
(at PND 46).
Blood samples, aAbs detection
All animals were withdrawn around 100–200 μl of blood
as a baseline sample (on PND 32) by lateral tail vein in-
cision. The animals were not anesthetised nor con-
stricted: they were gently allowed to move semi-freely
on the cage-top grid, while the experimenter was hold-
ing the tail to proceed with the incision (using a blade)
and with blood collection (using a sampling vial), then
left to freely-moving recovery over a cage-top grid for
10 sec. For mice of batch I, blood was collected at sacri-
fice (PND 49, i.e. three days after boost). Mice anesthe-
tised with xilazine and ketamine (10:100 mg/kg) were
bled by intra-cardiac puncture. For mice of batch II,
blood was obtained at PND 68, i.e. three weeks after the
boost, by lateral tail vein incision (as above). Samples
were centrifuged at 3,500 rpm for 20 min, and plasma
was stored at −80°C until subsequent analysis. In this
way, each mouse provided two samples differing for
“timing” of withdrawal (i.e., one baseline sample at PND
32 and one after-boost sample, at PND 49 in batch I and
PND 68 in batch II). The difference in “end sampling”
between the batches (i.e., batch I = 3 days after-boost
versus batch II = 3weeks after-boost) allowed to test 1)
whether the immunization was effectively generating
DAT aAbs (in batch I), and 2) whether this phenomenon
recovered long after the boost (in batch II).
Peptide fragments of DAT were used as antigens, to
detect plasma aAbs levels by means of a modified ELISA
[41,42]. In brief, the plasma samples (diluted 1:20,000)
were applied (100 μl) on the immuno-plate (Costar,
USA) containing the corresponding peptide fragment
(0.5 μg/well) and blocking agent. The plate was incu-
bated (1 h, 25°C) and washed (PBS with 0.05% Tween
20, pH 7.4). Peroxidase-labeled rabbit anti-mouse-Ig
(diluted 1:1000) secondary antibodies (Sigma, USA) were
added (100 μl) to each well and incubated (1 h, 25°C).
The plate was washed for 15 min with PBS and then the
substrate solution, o-phenylen-diamine SIGMA FAST™
(Sigma, USA), was added (100 μl) to each well. The reac-
tion was terminated by adding 2 N H2SO4, and the plate
was scanned at 450 nm on a Microplate Reader 3550
(Bio-Rad, USA). Sample buffer was included as a blank,
its value being subtracted from all samples (measured in
triplicate). This ELISA-based kit cannot discriminate
among the specific sub-classes or typologies of aAb.
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Mice of batch II were monitored for spontaneous home-
cage activity [49]. This was done thrice: 1, five days be-
fore immunization (baseline, PND 29–31); 2, after
immunization (PND 42–44); 3, five days after the boost
(PND 51–53). An automatic device was used, with small
passive infrared sensors on the top of each cage (Activi-
scope, Techno-Smart, Roma, Italy; www.newbehavior.
com), which detected any movement of mice (sampling
rate 20 events per second, 20 Hz). Data, recorded by a
computer with dedicated software, consist of cumulative
scores obtained during 60-min intervals, expressed as
counts per minute (cpm). Then, a circadian profile (24
points, 1 h each) of activity was obtained by averaging
three consecutive days of continuous registration within
individual cages. Spontaneous home-cage activity counts
were analyzed separately for diurnal and nocturnal
phases, which were further divided in early four-hour
and late eight-hour portions. The access of authorized
personnel to animal room was not restricted and fol-
lowed the routine schedule.
Novelty-seeking test
Apparatus
The experimental apparatus consisted of an opaque
Plexiglas rectangular box with smooth walls and floors,
which was subdivided into two compartments
(20x14x27cm each). The opening between the two com-
partments could be closed with a temporary partition.
Visual cues were associated with each compartment: one
compartment had a white floor, one white wall and three
black walls, while the other compartment had a black
floor, one black wall and three white walls. Each com-
partment was provided with four pairs of infrared photo-
beams, placed on the wall at a few cm above the floor,
spaced 5.5 cm apart. Beam interruptions were recorded
by a computer with custom-made software. The follow-
ing data were obtained automatically: 1) time spent in
each compartment, 2) activity rate in each compartment
(number of beam interruptions/second), and 3) fre-
quency of crossings between the two compartments
(number of crossings/minute). The whole session was
subdivided into bins, i.e. partial 5-min intervals. Two
boxes placed in a soundproof test room with dim illu-
mination were used; each subject was always tested in
the same box. The floor of the test apparatus was
cleaned after each animal.
Procedure
The experimental schedule (see ref. [50]) took a total of
four days, each subject (of batch II) being tested either
at PND 54–57 (one cage mate) or at PND 60–63 (the
other cage mate) between 13.00 and 17.00. Testing of
different experimental groups was counter-balancedacross time. During testing, the remaining cage mate
stayed in the animal room to prevent visual, auditory or
olfactory communication between cage mates. On the
first three days, mice were placed in the black floor/
white wall compartment of the apparatus for 25 min, in
order to familiarise with the procedure and apparatus,
while the other compartment was left unknown. On the
fourth day, animals were placed in the familiar compart-
ment as usual. Then, the partition separating the two
compartments of the apparatus was opened after
20 min, and mice were allowed to freely explore both
compartments of the apparatus for 15 min.
Delay-of-reward task
Apparatus
Four computer-controlled operant chambers (LabLink,
Coulbourn Instruments, Allentown, PA, USA) were
used. The chambers, made of aluminium and plexiglas
with grid floor, were provided with two nose-poking
holes, two feeder devices, two magazines (placed above
the nose-poking holes) where precision pellets (20 mg,
BioServ, Frenchtown, NJ, USA) were dropped, two
magazine lights, two chamber lights (one over each
magazine), and an aluminium platform designed to
make the food magazines accessible to mice by ramp
climbing. Nose-poking into the holes was detected by a
photocell and was recorded by a computer with custom-
made software, which also controlled food delivery. Each
mouse was tested daily in the same chamber. The grid
and walls of the chamber were cleaned after each
animal.
Procedure
Before the schedule started, animals (batch II) now at
adulthood (PND > 75) were familiarised with the preci-
sion (BioServ) pellets, provided in their home cage on
three successive days. Subsequently, each animal was in-
dividually placed in the operant chamber for 20 min
daily. After this session, mice were returned to their
home cages, where they were given standard food (ap-
proximately 65% of their ad libitum food intake), in
order to restrict them up to 90 ± 5% of their free-feeding
bodyweight. This procedure resembles the mild level of
food restriction, used in other studies [51-53] on deci-
sion making in rats and mice. Food restriction was
intended to increase animal’s motivation to work for
food delivery during training and testing phase.
The first day was just for familiarisation with the novel
environment (no pellets delivered). On the subsequent
day, the “training” phase started (8 days), providing bin-
ary choice between two alternatives. Now, nose-poking
in one of the two holes, termed small-and-soon (SS)
hole, resulted in the delivery of one pellet of food in one
magazine, whereas nose-poking in the other hole,
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of five pellets in the other magazine. After nose-poking
and before food delivery, the chamber light on the nose-
poked side was switched on for a 1-sec flash. After food
delivery on the nose-poked side, the corresponding
magazine light was switched on for 25 sec (time out,
TO), during which any additional nose-poking was with-
out any scheduled consequence. Mice were not trained
to a fixed criterion, rather they were provided a fixed
number (i.e., eight) of daily sessions, which enabled the
development of a reliable LL preference in nearly all of
animals (see ref. [50]).
During the “testing phase” (9 days), we evaluated (in)
tolerance to large-reward delay. Now, a delay was
inserted between nose-poking in the LL hole and the de-
livery of the five-pellet reward. The chamber light on the
LL side was switched on during the whole length of this
delay. Any additional nose pokes during this interval
were ineffective, i.e. not reinforced (“inadequate
responding”, [5,54]). The contingencies of the SS reward,
obtained by nose-poking at the SS side, were unchanged.
Under these conditions, nearly half of animals are
expected to shift in preference from LL to SS (“steep”
sub-population) while the other half maintain a clear-cut
preference for LL (“flat” sub-population, see [55]).
The whole experimental schedule took 20 days; sub-
jects were tested between 10.00 and 17.00. The delay
length was kept fixed for each daily session and was pro-
gressively increased across subsequent days (0, 5, 10, 17,
30, 42, 60, 90, 120, 150 sec). To compare present results
with similar studies, delay values should be converted
into odds [56]. The “relative” impact of present delays
did therefore follow this sequence: 0, 0.07, 0.14, 0.24,
0.42, 0.58, 0.83, 1.25, 1.66, 2.08 delay-equivalent odds.
The dependent variables were: 1) the choice (%) for the
large reinforcer, i.e. the percentage of preference for LL
over total choices; and 2) the “slope” of the preference-
delay curve. For each individual mouse, the slope
value was calculated using the Microsoft Excel “slope”
function, with LL-preference as the y-axis data and log
(delay + 1) as the x-axis data [57].Monoamine measurement ex-vivo
Five days after the delay-of-reward task, at 3.5 months of
age, mice (batch II) were sacrificed; brains were quickly
removed, dissected on dry ice and stored at −80°C. Con-
centrations of serotonin (5-hydroxy-triptamine, 5-HT),
dopamine (DA) and their metabolites, 5-hydroxy-indole-
acetic acid (5-HIAA), 3,4-dihydroxy-phenyl-acetic acid
(DOPAC) and homo-vanillic acid (HVA), were then
assessed in the prefrontal cortex (PFC), striatum (whole
complex, including both dorsal and ventral portions). In-
deed, the behavioural flexibility assessed by the delay-of-reward task is well known to depend on the interplay
between PFC and striatum [58-64].
Quantification of these monoamines, expressed as ng/
dg wet tissue, was carried out using a modified version
of the classical high performance liquid chromatography,
combined with an electrochemical detector (HPLC-EC),
as described by others [65,66]. These data provide infor-




To detect differences due to the immunization proce-
dures on the data collected as mentioned above,
repeated-measure ANOVAs were performed (Statview
II, Abacus Concepts, USA), with “Immunization” as a
between-subjects factor (namely, VEH versus DAT-i) and
“Time” as a within-subject factor (namely, the 24-level
scores, one per hour; or the 3-, 4-, or 5-level bins, one
per 5-min partial interval). Additional factors were intro-
duced when required, as outlined below. Multiple com-
parisons were performed for all parameters by the post-
hoc Tukey HSD test, an independent statistical source:
significant effects are drawn whenever differences be-
tween means are apparently beyond the Tukey HSD
threshold [67]. Statistical significance was set at p ≤ 0.05
(two-tailed).
ELISA-based aAbs detection
A 2x2x2 split-plot ANOVA was performed, by adding a
factor accounting directly for two separate batches.
Therefore, a between-subjects factor termed “Batch”
(namely, date of second withdrawal from either batch:
PND 49, 3 days after boost versus PND 68, 3 weeks after
boost) was added to the general design, where
“Immunization” (VEH versus DAT-i) was a between-
subjects factors and “Timing” (of withdrawal from the
same animal: baseline versus after-boost) was a within-
subject factor. Separate ANOVAs were performed within
either level of a given factor when allowed.
Subgroup analysis
According to a procedure which has been widely
adopted and validated in a number of studies [55,68],
each immunization group was divided into two sub-
groups, on the basis of slope in the preference-delay
curves. Mice with lower slope values (in algebraic value)
were assigned to one subgroup; mice with higher slope
values (in algebraic value) were assigned to the other
subgroup.
Delay-of-reward task
After the formation of subgroups, data were re-analyzed.
Selection of lower- versus higher- slope values resulted
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each pair of cage-mates, suggesting that mice within each
pair were statistically not independent. Therefore, the pair
of (non-independent) cage mates was the statistical block-
ing factor: a within-pair factor termed “Subgroup”
(namely, “low-slope” versus “high-slope” as defined above)
was added to the design, where “Delay” (9-level daily ses-
sion, 0-150 sec) was a within-pair factor, and
“Immunization” (VEH versus DAT-i) was a between-pairs
factor. The design was a 2x2x2 split-plot ANOVA.
Monoamine measurement
After the formation of subgroups, data were re-analyzed
by a two-way split-plot ANOVA, with a 2x2 design. The
within-pair factor termed “Subgroup” (“low-slope” versus
“high-slope” as defined above) was added to the between-
pairs “Immunization” (VEH versus DAT-i) factor.
Results
Generation of circulating anti-DAT aAbs, body-weight
The efficacy of immunization was assessed by measuring
plasma levels of aAbs targeting the DAT fragments, by
using a modified ELISA test (see Table 1). Accordingly,
after immunization with the antigen in CFA and boosting
with the antigen in IFA, the plasma aAbs levels of all mice
(i.e., both groups in both batches) were significantly ele-
vated, compared to the baseline condition (Timing, F
(1.95) = 11,12, p <0.05). Noteworthy, results clearly indi-
cate an immunizing effect of the DAT fragments (Batch x
Immunization, F(1,95) = 5.33, p <0.05). Indeed, increase of
DAT-aAbs titers was particularly marked in DAT-i mice
of batch I (six-fold over VEH controls).
As expected, plasma levels of DAT aAbs in all mice
(i.e., both VEH and DAT-i) were significantly higher in
samples taken a few days after the boost (in batch I), com-
pared to samples taken three weeks later (in batch II),
when they also became indistinguishable between VEH
and DAT-i groups (Batch, F(1,95) = 4.28, p <0.05). Thus,
as is classically the case, DAT-aAbs titers completely
recovered by three weeks [69]. Post-hocs confirmed the
profile just described, with a significant, six-fold difference
between the DAT-i and the control group (p <0.01) in
peak titers, observed in batch I a few days after the boost.Table 1 Circulating aAbs against DAT
Batch : 2nd withdrawal 3 days after boost 3 weeks after boost
VEH controls 385 ± 118% 157 ± 140%
DAT-i mice 2248 ± 866% ** 156 ± 108%
Mean (±SEM, n = 12 per group) percent increase in plasma levels of DAT-aAbs
titers in the second withdrawal compared to baseline, as a function of
immunization group. Each mouse provided two samples differing for “timing”
of withdrawal (i.e., baseline sample at PND 32 versus a second after-boost
sample). The “batches” differed (see Experimental Scheme 1) for the second
withdrawal, which was taken at PND 49 in batch I and PND 68 in batch II
(i.e., 3 days after boost versus 3 weeks after boost). ** p < 0.01 between DAT-i
and VEH control group.This difference was not found in samples from batch II,
taken three weeks after the boost. Therefore, two separate
analyses were carried out within the immunization factor.
Within the DAT-i group, significance emerged for
batch (F(1,53) = 3.83, p <0.05), timing (F(1,53) = 7.29,
p <0.05), and their interaction (Batch x Timing, F(1,53) =
3.16, p <0.05). DAT-fragment immunization significantly
elevated DAT aAbs titers, twenty-fold compared to base-
line. These levels reached peak values in batch I, few days
following the boost. In batch II, where the second sample
was taken three weeks later, aAbs levels were still slightly
elevated over the baseline, but markedly recovered in
comparison to batch I. As for the control group, plasma
aAbs levels were slightly but significantly elevated by VEH
alone (Timing, F(1,42) = 4.49, p <0.05). This represents a
non-specific stimulation (by CFA and IFA), found for the
few days following the boost, with slight and non-
significant recovery afterwards. Such a profile of results
serves to demonstrate indeed that the immunization
procedure was fully able to stimulate a reaction by the
immune system. A very small (three-fold) increase of
DAT aAbs was transiently generated also in the absence
of the antigen in VEH controls, while the presence of the
peptide immunogen in DAT-i mice clearly led to strong
anti-DAT titers.
No difference in body-weight was produced in batch II
by the immunization procedure.
Peaks of activity in circadian rhythm
There were no significant group differences in the base-
line as well as the intermediate recording periods, taken
before first immunization and before the boost. Signifi-
cant effects emerged for the last recording period, taken
few days after the boost (at PND 51–53), but only when
analyzing separately the two activity peaks usually
observed in mouse circadian rhythm. Specifically, the
early four-hour portions of both diurnal and nocturnal
phases underwent ANOVA with a 4-level rather than
24-level "Time" factor as a repeated measure; findings
were then confirmed by Student’s T tests performed on
total portion’s score. After offset (9 h-12 h) of room
light, we found a main immunization effect in the
ANOVA, F(1,10) = 4.67, corresponding to t(10) = 2.16,
.05 < p < .10, for the nocturnal peak; after onset (21 h-24 h)
of room light, we found a main immunization effect in
the ANOVA, F(1,10) = 3.31, corresponding to t(10) = 1.82,
.05 < p < .10, for the diurnal peak. The activity full (24 h)
profile was then screened with Tukey HSD.
At light-offset, VEH-injected controls showed peak ac-
tivity followed by a sharp decrease afterwards, as wit-
nessed by a clearly significant difference found between
11 h and 12 h (see Figure 1, # symbol). Interestingly,
after light-offset, DAT-i mice displayed a prolonged peak
of activity, with no evidence of such a sharp decrease:
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tinuing well after 12 h. Indeed, a relative minimum for
DAT-i mice was found at 14 h, followed by a sharp and
significant increase between 14 h and 15 h (see #
symbol). Compared to the profile of VEH mice, data
suggest a 2 h-longer peak at wake-up, with the relative
minimum of activity being shifted onward (from 12 h to
14 h) in DAT-i ones.
Moreover, VEH-injected controls showed a sharp de-
crease of activity after light-onset, as witnessed by a clear-
cut and significant difference found between 22 h and
23 h (see # symbol). Such a profile was anticipated in
DAT-i mice, occurring 1 h earlier between 21 h and 22 h.
Compared to VEH mice, therefore, the starting point in
resting phase of circadian activity was anticipated (from
22 h to 21 h) in DAT-i ones. However, the Tukey HSD sug-
gested for DAT-i mice a slight elevation of spontaneous ac-
tivity at 4 h and 5 h (see Figure 1, * symbol), namely in the
very middle of their resting period.Figure 1 Circadian Rhythm of Spontaneous Activity. Mean (±SEM, n = 6
per home cage (sensor rate 20 Hz). Nocturnal (upper panel) and diurnal (lo
the boost with DAT fragment (DAT-i) or VEH. The 24-h profile of one-hour
registration. * p < 0.05 between DAT-i and VEH control group; # p < 0.05, co
immunization group.In brief, DAT-fragment immunization produced: 1) a
2 h-longer peak of activity seen at light-offset; 2) a
1 h-anticipated beginning of rest after nocturnal daily
activity; and 3) a wake-up attempt during the middle of
the daylight.
Reactions to novel environments
The ANOVA on data from the first day of exposure
to the novel environment yielded an effect of time,
F(4,88) = 75.4, p < .001, but not of immunization,
F(1,22) = 2.94, p > .10, NS. Activity levels were indistin-
guishable both after 5 min of exposure, suggesting a simi-
lar novelty-induced peak (2.7 ± 0.2 in average for both
groups), and after 25 min of exposure (1.5 ± 0.1 in average
for both groups), suggesting a similar habituation to
novelty.
The ANOVAs on the testing day did not yield signifi-
cance for immunization effects nor for their interaction
with time. As a matter of fact, the two groups did notpairs) counts per minute (cpm) by undisturbed mice, housed in pairs
wer panel) activity was recorded for 3 days (PND 51–53), five days after
points was then obtained by averaging the 3 days of continuous
mpared to the previous or the following 1-h point within the same
Adriani et al. Behavioral and Brain Functions 2012, 8:54 Page 8 of 14
http://www.behavioralandbrainfunctions.com/content/8/1/54differ in time spent in the novel side, activity in either
side, nor crossings between sides (see Table 2).
Choice behaviour with delayed reward
ANOVA revealed a trend for delay, F(9,90) = 1.64, .05 <p< .10,
delay by immunization, F(9,90) = 1.61, .05 < p < .10,
and significance for delay by immunization by sub-
group, F(9,90) = 1.88, p < .05. Such a complex pattern
of results was first investigated with post-hoc analyses,
aimed at comparing the two subgroups (see # symbols in
Figure 2). Within the VEH controls, a significant differ-
ence between subgroups appeared only for delays of 90s,
120 s, 150 s. At these points, classical “flat” and “steep”
profiles emerged (Figure 2, left panel), as expected [55]:
the former subgroup did not abandon its original prefer-
ence for LL, whereas the latter exhibited a prominent shift
towards SS, whereby their preference eventually stabilized
around chance level.
In clear contrast, within the DAT-i mice, the lower-
slope subjects (termed “inflexible”) were characterized
by not showing any steepness at all (Figure 2, right
panel): this subgroup was just fluctuating between 65%
and 75%, suggesting a rigid or stuck preference. Con-
versely, the higher-slope subjects turned out to be char-
acterized by a marked upward steepness (i.e., “flexible”
but in the opposite direction): this subgroup started with
a scarce performance at 0 s, and then displayed progres-
sively more choices for LL options until a peak was
reached at 60s. Noteworthy, these peculiar positive-slope
mice were apparently slow in developing a preference
for LL; they eventually showed some indication of tem-
poral discounting, but only at the longest delay interval
(150 s). Such kind of behavioural profiles shall not be
interpreted as an index of impulsivity, but rather in
terms of choice flexibility. This profile of findings was
confirmed when separate analyses were run for either
sub-population, followed by post-hoc analyses aimed at
comparing DAT-i to VEH mice (see * symbols in
Figure 2).
The two sub-populations with higher slope values
(open circles in Figure 2) comprised “flat” VEH versus
“slow” (flexible) DAT-i mice. The ANOVA did not yield
significance for delay effects, nor for the interaction with
immunization. However, a significant difference emergedTable 2 Reaction to novelty in VEH and DAT-i mice, in a
novelty-seeking test
Parameter Activity rate Time (%) in novel Crossing/min
VEH controls 3.79 ± 0.21 79.7 ± 1.09 2.55 ± 0.26
DAT-i mice 4.10 ± 0.22 78.6 ± 1.75 2.98 ± 0.33
After a three-day familiarization to one side, mice had free-choice access to a
novel side of the apparatus. Mean (±SEM, n = 12 per group) activity rate
(number of beam interruptions per second), time (%) spent in the novel side,
and frequency of crossing to the familiar side, measured via photo-beam
interruptions by mice on the testing day.at delays of 60s and 90s, with “flat” VEH mice showing
lower LL preference than “slow” (flexible) DAT-i mice.
This finding indicates that - although less flexible - sub-
jects among VEH controls with a “flat” profile were in-
deed capable of reacting to delay intervals (i.e., by
showing a transient shift towards SS at 60s and 90s then
followed by a robust recovery in the expression of LL
preference). Conversely, at delays of 60s and 90s, the
“slow” (flexible) DAT-i subjects were still developing ini-
tial LL preference. Compared to VEH mice, a sign of re-
action to delay was only seen at 150 s (not at 60s), thus
confirming a flexible but very slow reactivity to task con-
tingencies in these DAT-i mice.
The two sub-populations with lower slope values
(closed circles in Figure 2) comprised “steep” VEH ver-
sus “stuck” (inflexible) DAT-i mice. ANOVA yielded sig-
nificance for delay, F(9,90) = 1.86, p < .05, and for the
interaction with immunization, F(9,90) = 1.91, p < .05.
Post-hoc comparisons revealed a significant difference
between “steep” VEH and “stuck” DAT-i mice at delays
of 30s (with a higher LL preference in the former) and
again at 90s, 120 s, 150 s (with a lower LL preference in
the former). Data confirmed that flexible subjects among
VEH controls (i.e., those with a “steep” profile) devel-
oped (for delay > 60s) a robust shift due to a temporal
discounting, which stabilized around chance level
namely with choosing SS and LL equally often. Con-
versely, the sub-population of “stuck” (inflexible) DAT-i
mice did not show any contingency-driven change nor
any transient attraction towards either LL or SS. Their
apparent performance just fluctuated around an average
70% of LL preference.
Peculiar performance of inflexible DAT-i mice (with a
“stuck” profile) was confirmed by data collected during
the training phase: number of sessions with a significant
preference for LL differed across subgroups. These
values were indistinguishable between less versus more
flexible VEH sub-populations (3.5 ± 0.8 days in both sub-
groups), suggesting a similar development of LL prefer-
ence. Conversely, this parameter was significantly higher
in inflexible DAT-i mice than in flexible ones (5.5 ± 0.8
versus 2.0 ± 0.4 days, respectively, when comparing the
two profiles: “stuck” versus “slow”). These data suggest
somewhat an earlier manifestation of LL preference in
the former subgroup. Most of the inflexible DAT-i mice
(with a “stuck” profile) displayed LL preference by the
third training session (which for mice is surprisingly too
quick, see ref. [70]), and then maintained it throughout
the entire task.
In summary, VEH mice exhibited the well expected
and clear-cut reaction to the increasing delay. Individual
differences emerged, with one sub-population showing
inflexible choice (i.e., actively choosing to maintain a LL
preference, after a transient attraction towards SS) and
Table 3 Neuro-chemical parameters in striata of VEH and
DAT-i mice
Parameter DA DOPAC HVA
VEH inflexible (“flat”) 317.5 ± 47.5 91.3 ± 22.0 59.5 ± 5.7
VEH flexible (“steep”) 368.5 ± 35.9 77.2 ± 20.0 65.4 ± 2.5
DAT-i flexible (“slow”) 320.8 ± 30.4 53.8 ± 14.9 75.2 ± 9.7 *
DAT-i inflexible (“stuck”) 452.3 ± 90.9 124.9 ± 22.2 *# 88.3 ± 9.2 *
Mean (±SEM, n = 6 per sub-population, N = 24) concentration (ng/dg wet
tissue) of striatal DA and its metabolites, as a function of immunization group
and of the sub-population as emerged in the operant-behaviour task.
* p < 0.05 between DAT-i and VEH control group within the corresponding
slope-defined sub-population; # p < 0.05 between sub-populations within
the same immunization group.
Figure 2 Choice between Rewards, Reaction to Delay. Mean (±SEM, n = 6 per sub-population) choice (%) for the large but late (LL) reward in
mice, immunized with DAT fragment (right panel) or vehicle alone (left panel), in a delay-of-reward task. Two sub-populations were formed,
based on the slope of preference curves (see Methods). Among VEH controls, individuals segregated into either a flexible (with a “steep” profile,
black points) or an inflexible (with a “flat” profile, white points) subgroup. Among DAT-i mice, individuals segregated into either an inflexible (with
a “stuck” profile, black points) or a flexible (with a “slow” profile, white points) subgroup. * p < .05 between DAT-i and VEH controls; # p < 0.05
when comparing sub-populations (low- versus high-slope) within the same immunization group.
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quickly shifting from LL preference towards SS). In clear
contrast, performance of DAT-i mice was quite impaired.
Half of subjects were inflexible (i.e., stuck to a rigid choice
habit despite a progressively increasing delay); the other
half of mice were just residually flexible (i.e., considerably
slow to acquire and to shift their choice strategies).
Forebrain monoamine impairment
DA levels
No overall difference was found between DAT-i and
VEH mice in the striatal levels of DA and of DOPAC,
the major metabolite of DA (see Table 3). However,
when considering the classification into two sub-popula-
tions, which were evidenced at behavioural level, marked
differences appeared (immunization x subgroup, F(1,
20) = 4.52, p < 0.05). Namely, within the DAT-i group, a
significantly higher DOPAC concentration was found in
the striatum of inflexible mice (with a “stuck” profile, see
black circles, Figure 2) compared to flexible ones (with a
“slow” profile, see white circles, Figure 2). Overall, DAT-
i mice showed significantly higher striatal levels of HVA
than VEH mice (immunization, F(1, 20) = 6.86, p < 0.05).
Considering the PFC, no effect of immunization
emerged. However, a significant difference emerged be-
tween the two separate sub-populations (subgroup, F
(1,20) = 7.24, p < .01). Indeed, the lower-slope subgroup
(formed by mice with a “steep” or a “stuck” profile, see
black circles, Figure 2) had higher levels of HVA (10.49
± 0.79 vs 7.97 ± 0.45) than the higher-slope subgroup
(consisting of mice with a “flat” or a “slow” profile, see
white circles, Figure 2). These data may suggest a bettercortical function in the latter subgroup of subjects. Note
that mice with a “flat” or a “slow” profile do share a
common feature, that is, they display as a whole a more
marked attraction to LL, compared to mice with a
“steep” or a “stuck” profile.
5-HT levels
DAT-i mice exhibited significantly higher levels of 5-HT
in the striatum (33.06 ± 2.19 vs 25.71 ± 2.82), when com-
pared to the VEH controls (immunization, F(1, 20) =
4.43, p < 0.05). The elevation in 5-HT levels may com-
pensate for the striatal DA impairment in DAT-i sub-
jects. No effects whatsoever were found in the PFC.
Discussion
Immunization with DAT fragments generated a transient
auto-immune response, with a marked elevation in titers
of circulating aAbs directed against DAT. Notably, this re-
sponse resulted in long-lasting impairment of striatal DA
Adriani et al. Behavioral and Brain Functions 2012, 8:54 Page 10 of 14
http://www.behavioralandbrainfunctions.com/content/8/1/54systems’ function, with enduring rise of HVA and also
DOPAC levels. Such neuro-chemical sequel was consist-
ently associated with a profile of behavioural modifica-
tions, including a rearrangement in patterns of nocturnal
activity and diurnal resting, spontaneously expressed
within home-cages settings. Such subtle effects in the
wake-sleep rhythm were expected based on earlier data
[49,55]: these effects are relevant, since they denote a
longer and more intense beginning as well as an earlier
end of the daily spontaneous activity in DAT-i mice. Inter-
estingly, a considerable impairment of their adaptive cap-
acity was found when considering choice behaviour in the
delay-of-reward task contingencies.
Changes in behavioural flexibility and impairment in
forebrain DA
In a classical study from our group [55], we assessed
spontaneous home-cage activity in the SHR rat, a vali-
dated model for ADHD [54]. Interestingly, these rats
showed increased activity during specific time-points of
the dark phase, as well as peaks of activity with interrup-
tion of rest during the light phase. Thus, the circadian
rhythm of present DAT-i mice, consisting in a prolonged
peak of spontaneous activity after wake-up, an antici-
pated start for the resting period, as well as the tendency
for diurnal sleep to be interrupted by a wake-up peak,
shares some interesting features with these rats model-
ling for ADHD.
As for operant-choice behaviour, control mice were
able to perform the whole delay-of-reward task correctly.
As expected, all of the subjects developed a clear LL pre-
ference during training phase and then modified their
choice preference according to the introduction of
delays. Indeed, they displayed either a slight and transi-
ent or a robust and persistent shift towards SS, denoting
their subjective discounting of value attributed to the LL
option. As classically reported with this kind of proto-
cols [57,71], discounting (or not) of LL value identifies
these individuals as more (or less) delay-intolerant.
Notably, mice of the DAT-i group appeared greatly
impaired in operant choice between two alternatives dif-
fering for reward size and delay contingencies. Note-
worthy, they were perfectly capable to associate nose-
poking in either hole with the corresponding magazine
of food-delivery. Nose-poking was followed by ramp
climbing and food eating, ruling out major biases due to
gross motoric or cognitive deficit. Their impairment was
apparently specific to the formation and/or the flexible
modification of a choice strategy. In fact, half of the sub-
jects (termed DAT-i flexible, with a “slow” profile) were
hardly able 1) to discriminate the difference in reward
size between LL and SS, and 2) to detect and/or react to
delay intervals. These subjects were still flexible, but
appeared to be slow both in developing preference forthe larger-size reward and in reacting to its delay; this,
despite extensive training and testing. In the other half
of subjects (termed DAT-i inflexible, with a “stuck” pro-
file), a more marked impairment emerged: a net prefer-
ence for LL seemed to be expressed, which was likely
the result of a rigid pattern of choice. Closer analyses on
sequence of choices may be useful to ascertain if this
was indeed a habit (informal observation of mice sug-
gested that each SS option was followed by two LL
options quite regularly).
Present DAT-i mice displayed two profiles, consisting
of either slower acquisition of LL preference plus late re-
action to delay, or rigid habit-based responding. Both
profiles may be interpreted as reduced or entirely
impaired ability to develop a new pattern of choice and/
or to modify a previously acquired one. Thus, as an en-
during consequence of DAT auto-immune reactions,
functional impairment can be proposed for DAT-i mice
within the striatum (possibly, its dorso-medial region).
In other words, a difficulty in modifying choice strategy
and/or a rigid preference profile, shown by DAT-i sub-
populations of mice, reflect different degrees of inflex-
ibility due to impaired striatal function. Neuro-chemical
data are in agreement with this notion since both sub-
groups of DAT-i mice showed enhanced HVA (alone or
together with DOPAC) in the striatum. Since DA levels
were unchanged, it can be proposed that excessive DA
metabolism occurred as an enduring adaptation to the
auto-immune insult. None of the multiple possibilities
can be dismissed (excessive DA synthesis, release or
leakage; reduced re-uptake by diminished DAT function
or levels); however, an enhanced DA catabolism (with a
dynamic limit in HVA fate and its consequent accumula-
tion) seems to be more likely. In some cases, a very big
HVA accumulation was denoted by a rise of DOPAC, its
intermediate precursor. DOPAC was increased in inflex-
ible (with a “stuck” profile) but not in flexible (with a
“slow” profile) DAT-i mice, suggesting that rate of DA
metabolism was of an extreme extent in the former sub-
group, causing the accumulation of catabolic products
deriving from DA.
Moreover, independently from immunization, enhanced
products of DA metabolism were found in the PFC of
some individuals: specifically, subgroups with a “flat” or a
“slow” profile displayed more attraction to LL together
with lower HVA in the PFC. Conversely, enhanced DA ca-
tabolism may suggest poorer dopaminergic function
[72,73], so that cortical control would be worsened, in the
subjects with a “steep” or a “stuck” profile. These data
point to the role of PFC as subserving inhibitory control
over the striatum [74]. The physiological role of PFC is
promoting the development of inhibition over impulsive
drives, at least in the less flexible sub-population within
VEH controls; a reduced PFC function may thus explain
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subjects within VEH controls. Following immunization,
and in the presence of a compromised striatal function,
the PFC may allow residual learning abilities as observed
within flexible DAT-i mice. A relatively reduced function
within the PFC, on the other hand, would contribute to
the choice-rigidity observed in inflexible subjects among
DAT-i mice.
Since the PFC is known to be devoid of DAT, it can-
not have been a direct target of the DAT-directed
auto-immunity. Such PFC-related features were likely pre-
existing across groups. It is noteworthy that we were pres-
ently able to identify two separate subgroups of mice,
based on their behavioural strategy in the operant choice
task: differing levels of flexibility could be associated with
diverse DA dynamics in the PFC, and this in the absence
of any difference concerning levels of 5-HT nor of its
metabolite.
Implications: auto-immunity in neuro-psychiatry
To interpret the present results, we propose that a transi-
ent rise of DAT aAbs, generated by immunization with
DAT fragments, induced sequelae onto the striatal com-
plex (possibly in its specific sub-regions), and a long-
lasting interference with the corresponding behaviours.
Thus, auto-immune reactions, with an increase of circu-
lating aAbs to specific neural targets, may contribute to
the etiology of psychiatric symptoms, at least to a certain
extent [43-46]. There are many open issues, however,
about such a working hypothesis, namely: 1) how can
anti-CNS aAbs develop; and 2) how can these aAbs reach
their CNS targets and exert their consequences. To cover
the first issue (generation of anti-CNS aAbs), two hypoth-
eses can be proposed. First, antibodies generated by im-
mune reactions against an infectious agent may turn out
to recognize some epitopes on healthy cells (see [75]), a
typical mechanism proposed to account for some neuro-
behavioural alterations observed within the so-called
pediatric autoimmune neuropsychiatric disorders asso-
ciated with streptococcal infections (i.e., PANDAS). Sec-
ond, neuro-receptor fragments may themselves cause
generation of auto-immune antibodies, at least in some
cases. Indeed, since receptors and proteins expressed by
neurons are fragmented during degradation, these frag-
ments may occasionally enter into the bloodstream and
act as antigenic peptides [76,77]. This second hypothesis
obviously postulates a temporary leakage of blood–brain
barrier (BBB).
Such hypothesis should also be involved under the sec-
ond open issue (i.e., reaching of CNS targets by aAbs),
and therefore deserves more investigation. The BBB pre-
vents developing B-cells in the bloodstream from being
exposed to unique brain antigens: therefore, there are no
mechanisms to establish tolerance to brain antigensand/or to prevent the production of antibodies against
them. BBB failure would facilitate drainage of CNS anti-
gens to peripheral lymphoid organs: subsequently, B-cell
recognition of CNS antigens would cause: 1) B-cell pro-
liferation and aAbs production; 2) presentation of CNS
antigens to T-cells, with interactions between T- and
B- cells amplifying the auto-immune response; 3) sug-
gestion that activated B-cells may release aAbs into the
circulating bloodstream [28,29]. A related question,
about the present anti-DAT aAbs, is then how can they
reach the DA pathway, and where the auto-immune
insult actually takes place.
As a matter of fact, DAT is not only present in striatal
synapses: DA neurons in ventral mesencephalon, i.e. in
the Substantia Nigra (SN) pars compacta (SNc; cell
group A9) and in the Ventral Tegmental Area (VTA; cell
group A10), are enriched with moderate to high DAT
immuno-reactive intensity [78,79], where it is concen-
trated in perikarya, dendrites, and axons. The presence
of DAT in the somato-dendritic and axonal compart-
ments of the VTA and the SNc is particularly intriguing,
since the nigro-striatal dopaminergic system is specially
sensitive to changes in BBB integrity [80], a feature re-
cently associated to Parkinson’s disease (PD). The spe-
cific vulnerability of nigral dopaminergic neurons has
already been demonstrated in many degeneration mod-
els: the Vascular Endothelial Growth Factor (VEGF),
Histamine, and Lipo-poly-saccharide (LPS), are all able
to disrupt the BBB in the entire ventral mesencephalon,
and to reduce cell bodies and fibres of DA neurons in
the SNc [81-83]. Previous studies have suggested that
microglial density is high in the SNc [84], mediating ex-
cessive inflammatory reactions and causing dopamin-
ergic neurons in the SNc to be vulnerable: any transient
BBB disruption in the SNc likely results in the vigorous
infiltration of neutrophils, which in turn could trigger a
vicious cycle of astrocyte and endothelial cell damage,
BBB permeability, and further neutrophil infiltration
[85]. Therefore, since BBB integrity is crucial to preserve
dopaminergic neurons, we propose that a transiently dis-
rupted BBB, in association with immunization proce-
dures, opened the ventral mesencephalon to the action
of anti-DAT aAbs, with the permanent consequence of a
reduced number of DA cell bodies in the SNc and of
subsequent alterations within mesencephalic fibres pro-
jecting to the dorsal striatum.
Limitations and future perspectives
The present results do raise a number of questions
which remain unfortunately unanswered. For instance,
details about production of DAT aAbs as well as in vivo
effects of these aAbs on DAT activity are unknown yet
(though, check with ref. [86]). Future investigation is
warranted to gather full details of antibody development,
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selectivity of effects on DAT activity. We underline that
several experimental approaches could be used.
In order to address the first point (i.e., how can DAT
aAbs develop in pathogenesis), two main questions
should be answered: Are neuro-receptor fragments pro-
duced in vivo as a side consequence of protein degrad-
ation? Are neuro-receptor fragments able to efflux
across the BBB? In addition, once postulated that anti-
DAT aAbs could be somehow produced, it would be
interesting to investigate the BBB influx in the mouse,
using isolated/purified and I-125/123/131-radiolabelled
anti-DAT aAbs. An alternative way to explore the BBB
permeability issue could be to detect these aAbs directly
within the brain tissues or at least in the CSF.
Finally, it would be helpful to differentiate between a
direct effect (linked to putative DAT protein / anti-DAT
aAb interaction) and indirect effects brought by circulat-
ing aAbs, as it cannot be excluded that central conse-
quences may arise without the need for these aAbs to
cross the BBB. In this line, a direct intra-cerebral injec-
tion of these anti-DAT aAbs would allow to study the
putative direct effects on functional DAT activity and be-
haviour. In vivo micro-dialysis and fast-scan cyclic vol-
tammetry (FSCV) could be used to assess the actual DA
dynamics in brain areas like e.g. the dorsal and ventral
striata.
Concluding remarks
Present findings indicate a profile of slight spontaneous
hyperactivity in DAT-i mice, in the form of a 2 h-longer
wake-up peak and a wake-up attempt during rest (spon-
taneous rhythm in their home cages) together with
reduced or overtly impaired patterns of flexibility (oper-
ant choice task in Skinner-box cages). It is well known
that the ventral portion of the striatum subserves a mo-
tivational drive to flexibly change choice strategies
[58,60,64]. After ventral striatum has provided motiv-
ation, such behavioural flexibility requires the recruit-
ment of specific circuits within dorsal striatum [59,62]; if
these are compromised, the expression of habits is
observed, whereby semi-automatic behaviour does not
respond to devaluation of its outcomes [61,63].
Our data are consistent with a functional impairment
of the striatal complex, as a long-lasting consequence
tapping onto the dopaminergic pathways and owing to
the DAT immunization. Namely, the transient (but de-
tectable) rise in circulating aAbs, generated by specific
neuro-receptor fragments used as antigen, possibly to-
gether with a concomitantly permeable BBB (occasion-
ally possible in stressful conditions; see [87]), might have
generated persistent neuro-behavioural sequelae. Simi-
larly, in a recent study [49], mice specifically immunized
with fragments of glutamate receptors (GluR1) alsodemonstrated altered spontaneous activity and a stereo-
typed behavioural syndrome in response to a novelty-
induced stress. A possible limitation in our study may be
the lack of a further control group, immunized with a
non-specific peptide. It is not easy however to figure out
what this control peptide could be, since the exact se-
quence of the DAT antigens is currently protected
information.
In conclusion, brain-directed auto-immune responses
are likely to interfere with (or produce enduring impair-
ments to) function of brain areas, with all the conse-
quences thereof. More research effort is needed to verify
potential psycho-immune alterations, via changes in the
brain and behaviour of immunized mice. An altered
psycho-immune modulation of neuro-receptors, like
GluR1 or DAT, may play a role in vulnerability to neuro-
psychiatric disorders like ADHD and OCD, as well as
other impulse-control disorders like e.g. pathological
gambling and sensation seeking.Abbreviations
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